Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smart sensors to monitor rare muscle disease treatment

NCT ID NCT07226830

Not yet recruiting Knowledge-focused Sponsor: BioSensics Source: ClinicalTrials.gov ↗

First seen Nov 12, 2025 · Last updated May 25, 2026 · Updated 28 times

Summary

This study will see if wearable sensors and smartphone apps can effectively track disease symptoms in 25 people with generalized myasthenia gravis who are starting treatment with VYVGART or VYVGART Hytrulo. Participants will wear sensors to measure physical activity, speech, and daily function over 16 weeks. The goal is to learn if digital tools can provide reliable, remote monitoring of the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital, Neuromuscular Diagnostic Center

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.